published meta-analysis   sensitivity analysis   studies

interferon in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsKalil (ACTT-3), 2021 1.74 [0.51; 5.93] Pandit, 2021 0.95 [0.02; 50.33] Shashi Bhushan, 2021 4.39 [0.20; 98.33] 1.86[0.62; 5.58]Kalil (ACTT-3), 2021, Pandit, 2021, Shashi Bhushan, 202130%1,258moderatenot evaluable deathsdetailed resultsDarazam, 2021 1.21 [0.65; 2.25] Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25] Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92] Fu, 2020 1.00 [0.02; 51.66] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] Li, 2021 1.04 [0.02; 53.73] Pandit, 2021 0.95 [0.02; 50.33] Rahmani, 2020 0.29 [0.05; 1.56] Shashi Bhushan, 2021 4.39 [0.20; 98.33] SOLIDARITY (interferon), 2020 1.16 [0.96; 1.40] Synairgen SG016, 2020 0.16 [0.01; 3.31] Wang, 2020 (REV) 1.00 [0.02; 52.54] 1.11[0.94; 1.32]Darazam, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Fu, 2020, Kalil (ACTT-3), 2021, Li, 2021, Pandit, 2021, Rahmani, 2020, Shashi Bhushan, 2021, SOLIDARITY (interferon), 2020, Synairgen SG016, 2020, Wang, 2020 (REV)120%5,995moderatelow deaths (time to event analysis only)detailed resultsKalil (ACTT-3), 2021 1.74 [0.51; 5.93] 1.74[0.51; 5.93]Kalil (ACTT-3), 202110%969NAnot evaluable clinical deteriorationdetailed resultsLi, 2021 0.52 [0.02; 15.78] Synairgen SG016, 2020 0.50 [0.18; 1.38] Wang, 2020 (REV) 1.00 [0.02; 52.54] 0.52[0.20; 1.35]Li, 2021, Synairgen SG016, 2020, Wang, 2020 (REV)30%243moderatenot evaluable clinical improvementdetailed resultsDarazam, 2021 1.37 [0.88; 2.13] Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] Li, 2021 1.76 [1.10; 2.81] Shashi Bhushan, 2021 0.68 [0.21; 2.20] Synairgen SG016, 2020 2.32 [1.07; 5.04] 1.42[1.00; 2.03]Darazam, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Kalil (ACTT-3), 2021, Li, 2021, Shashi Bhushan, 2021, Synairgen SG016, 2020667%1,515moderateserious clinical improvement (14-day)detailed resultsKalil (ACTT-3), 2021 1.01 [0.79; 1.29] Li, 2021 2.86 [1.24; 6.62] Pandit, 2021 8.77 [0.94; 81.67] Shashi Bhushan, 2021 0.68 [0.21; 2.20] 1.54[0.69; 3.39]Kalil (ACTT-3), 2021, Li, 2021, Pandit, 2021, Shashi Bhushan, 2021468%1,344moderatenot evaluable clinical improvement (28-day)detailed resultsLi, 2021 4.26 [1.10; 16.44] Synairgen SG016, 2020 3.15 [1.39; 7.14] 3.42[1.70; 6.88]Li, 2021, Synairgen SG016, 202020%195moderatenot evaluable clinical improvement (7-day)detailed resultsLi, 2021 1.83 [0.41; 8.14] Shashi Bhushan, 2021 1.91 [1.03; 3.53] 1.90[1.07; 3.35]Li, 2021, Shashi Bhushan, 202120%316moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsDarazam, 2021 1.37 [0.88; 2.13] Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12] Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] Li, 2021 1.76 [1.10; 2.81] Rahmani, 2020 3.41 [1.33; 8.73] 1.55[1.07; 2.24]Darazam, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Kalil (ACTT-3), 2021, Li, 2021, Rahmani, 2020671%1,379moderateserious death or ventilationdetailed resultsSOLIDARITY (interferon), 2020 1.05 [0.90; 1.23] Synairgen SG016, 2020 0.38 [0.09; 1.63] 0.83[0.35; 1.93]SOLIDARITY (interferon), 2020, Synairgen SG016, 2020246%4,100moderatenot evaluable hospital dischargedetailed resultsRahmani, 2020 3.44 [0.64; 18.49] Synairgen SG016, 2020 1.63 [0.61; 4.35] 1.97[0.84; 4.60]Rahmani, 2020, Synairgen SG016, 202020%167moderatenot evaluable hospitalizationdetailed resultsJagannathan, 2020 1.00 [0.14; 7.34] 1.00[0.14; 7.34]Jagannathan, 202010%120NAnot evaluable mechanical ventilationdetailed resultsDarazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67] Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67] Li, 2021 0.52 [0.02; 15.78] Rahmani, 2020 0.29 [0.05; 1.56] 0.74[0.34; 1.62]Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Li, 2021, Rahmani, 202040%240moderatenot evaluable viral clearance detailed resultsJagannathan, 2020 0.81 [0.56; 1.18] Li, 2021 7.68 [0.91; 65.15] Pandit, 2021 2.33 [0.55; 9.83] Shashi Bhushan, 2021 2.77 [1.44; 5.32] 1.98[0.76; 5.13]Jagannathan, 2020, Li, 2021, Pandit, 2021, Shashi Bhushan, 2021479%495moderatenot evaluable viral clearance (time to event analysis only)detailed resultsJagannathan, 2020 0.81 [0.56; 1.18] Li, 2021 1.74 [1.10; 2.75] 1.17[0.56; 2.48]Jagannathan, 2020, Li, 2021284%216moderatenot evaluable viral clearance by day 14detailed resultsLi, 2021 1.74 [0.71; 4.29] Pandit, 2021 10.23 [1.12; 93.35] Shashi Bhushan, 2021 0.00 [0.00; 0.01] 0.38[0.00; 46.74]Li, 2021, Pandit, 2021, Shashi Bhushan, 2021398%1,453moderatenot evaluable viral clearance by day 7detailed resultsLi, 2021 2.20 [0.95; 5.10] Pandit, 2021 2.33 [0.55; 9.83] Shashi Bhushan, 2021 2.77 [1.44; 5.32] 2.52[1.55; 4.09]Li, 2021, Pandit, 2021, Shashi Bhushan, 202130%375moderatenot evaluable ICU admissiondetailed resultsDarazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71] Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94] Rahmani, 2020 0.37 [0.14; 1.00] 0.49[0.24; 1.00]Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Rahmani, 202030%146moderatenot evaluable recoverydetailed resultsSynairgen SG016, 2020 2.19 [1.03; 4.67] 2.19[1.03; 4.67]Synairgen SG016, 202010%101NAnot evaluable related SAE (TRSAE)detailed resultsWang, 2020 (REV) 0.49 [0.02; 15.31] 0.49[0.02; 15.31]Wang, 2020 (REV)10%48NAnot evaluable serious adverse eventsdetailed resultsJagannathan, 2020 1.00 [0.14; 7.34] Pandit, 2021 0.95 [0.02; 50.33] 0.99[0.17; 5.88]Jagannathan, 2020, Pandit, 202120%159moderatenot evaluable superinfectiondetailed resultsRahmani, 2020 0.18 [0.02; 1.59] 0.18[0.02; 1.59]Rahmani, 202010%66NAnot evaluable adverse eventsdetailed resultsJagannathan, 2020 1.33 [0.63; 2.78] Pandit, 2021 1.68 [0.47; 5.97] Wang, 2020 (REV) 0.28 [0.07; 1.08] 0.93[0.36; 2.43]Jagannathan, 2020, Pandit, 2021, Wang, 2020 (REV)357%207moderatenot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-03-28 16:16 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 517,881,904,882,897,896,899,1235,898,687,740,883,947 - roots T: 290